We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

89 hedge funds and large institutions have $364M invested in Aratana Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 24 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

50% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 24

10% more funds holding

Funds holding: 8189 (+8)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8% less capital invested

Capital invested by funds: $396M → $364M (-$31.9M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $48K

Holders
89
Holders Change
+8
Holders Change %
+9.88%
% of All Funds
2.56%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
36
Reduced
24
Closed
9
Calls
Puts
$48K
Net Calls
-$48K
Net Calls Change
-$48K
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$41.3M +$14.9M +1,052,147 +66%
Jennison Associates
2
Jennison Associates
New York
$38M +$7.5M +529,147 +28%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$33.4M +$12.1M +857,400 +67%
MAM
4
MPM Asset Management
Massachusetts
$32.7M -$9.84M -694,320 -25%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$19.9M
AllianceBernstein
6
AllianceBernstein
Tennessee
$16.9M +$1.46M +102,736 +10%
Massachusetts Financial Services
7
Massachusetts Financial Services
Massachusetts
$15.3M +$2.12M +149,919 +18%
BC
8
Broadfin Capital
New York
$12.8M +$2.13M +150,000 +22%
DM
9
Deerfield Management
New York
$12.3M
JP Morgan Chase
10
JP Morgan Chase
New York
$9.89M -$1.57M -110,979 -15%
BFA
11
BlackRock Fund Advisors
California
$9.41M +$5.34M +376,739 +167%
AWMDMG
12
Austin W. Marxe & David M. Greenhouse
New York
$9.37M
RIM
13
RS Investment Management
California
$8.88M -$143K -10,096 -2%
Vanguard Group
14
Vanguard Group
Pennsylvania
$8.61M +$793K +55,936 +11%
CIP
15
Chartwell Investment Partners
Pennsylvania
$6.74M +$426K +30,049 +7%
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$6.43M +$851K +60,032 +17%
WRF
17
Waddell & Reed Financial
Kansas
$6.41M -$646K -45,600 -10%
O
18
OppenheimerFunds
New York
$5.44M +$936K +66,052 +23%
Goldman Sachs
19
Goldman Sachs
New York
$4.72M -$231K -16,285 -5%
State Street
20
State Street
Massachusetts
$4.55M +$2.36M +166,633 +134%
Lazard Asset Management
21
Lazard Asset Management
New York
$4.38M +$437K +30,830 +12%
BIT
22
BlackRock Institutional Trust
California
$4.25M -$609K -42,985 -14%
Principal Financial Group
23
Principal Financial Group
Iowa
$3.85M -$113K -8,000 -3%
EAM
24
Eagle Asset Management
Florida
$3.79M -$1.51M -106,387 -30%
FAM
25
Fred Alger Management
New York
$3.53M -$899K -63,438 -22%

PETX Hedge Fund Activity: Q2 2014 in Review

89 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q2 2014, worth a combined $364M — down 8.1% from $396M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new PETX positions and 9 closed out — a net gain of 8 holders — while 36 added to existing stakes and 24 trimmed.

The largest buyer was Franklin Resources, adding an estimated $14.9M. The largest seller was MPM Asset Management, cutting an estimated $9.84M.

  • 89 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q2 2014, up from 81 in Q1 2014.
  • Funds reported $364M of Aratana Therapeutics, Inc. stock for Q2 2014, down 8.1% quarter-over-quarter.
  • 17 funds opened new Aratana Therapeutics, Inc. positions in Q2 2014 and 9 closed out, a net change of +8 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q2 2014 was Franklin Resources, an estimated $14.9M added.
  • The largest Aratana Therapeutics, Inc. seller in Q2 2014 was MPM Asset Management, an estimated $9.84M sold.

Based on aggregated 13F filings for Q2 2014.